- CAY10650
-
- $47.00
-
2026-07-14
- CAS:1233706-88-1
- Purity: 97.33%
- Supply Ability: 10g
|
| | CAY10650 Basic information |
| Product Name: | CAY10650 | | Synonyms: | CAY10650;1H-Indole-5-carboxylic acid, 3-(2-Methyl-1-oxopropyl)-1-[2-oxo-3-(4-phenoxyphenoxy)propyl]-;3-(2-Methyl-1-oxopropyl)-1-[2-oxo-3-(4-phenoxyphenoxy)propyl]-1H-indole-5-carboxylic acid;CAY10650, >=98%;CAY 10650;CAY-10650;CAY10650;CAY-10650;CAY 10650;CS-1520;3-isobutanoyl-1-[2-oxo-3-(4-phenoxyphenoxy)propyl]indole-5-carboxylic acid | | CAS: | 1233706-88-1 | | MF: | C28H25NO6 | | MW: | 471.5 | | EINECS: | 604-604-1 | | Product Categories: | | | Mol File: | 1233706-88-1.mol |  |
| | CAY10650 Chemical Properties |
| Melting point | 103-104℃ | | Boiling point | 685.4±55.0 °C(Predicted) | | density | 1.24±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMF: 20 mg/ml; DMSO: 20 mg/ml; DMSO:PBS (pH 7.2) (1:10): 0.1 mg/ml | | pka | 4.03±0.30(Predicted) | | form | Powder | | color | White to off-white |
| | CAY10650 Usage And Synthesis |
| Description | Cytosolic phospholipase A2α (cPLA2α) specifically catalyzes the hydrolysis of arachidonic acid from the sn-2-ester position of membrane phospholipids, playing a central role in initiating the synthesis of prostaglandins and leukotrienes, both important mediators of the inflammatory process. CAY10650 is a highly potent (IC50 = 12 nM) cPLA2α inhibitor. It demonstrates strong anti-inflammatory effects when applied topically at a dose of 0.1 mg/ear in a mouse model of acute irritant contact dermatitis. The phase I metabolite of this compound, CAY10641 , is also available. | | Uses | CAY10650 is a highly potent cytosolic phospholipase A2α (cPLA2α) inhibitor with an IC50 value of 12 nM. CAY10650 suppresses lipid droplets formation and PGE2 secretion[1][2]. | | in vivo | CAY10650 (50 μg/5 μL; Inject with topical eye-drop; Chinese hamsters) relieves acanthamoeba keratitis in vivo.[1]. | Animal Model: | Chinese hamsters with infected with parasite-laden contact lenses[1] | | Dosage: | 50 μg/5 μL | | Administration: | Inject with topical eye-drop under the contact lens; three times a day for 6 days and topically on days 7 to 20 postinfection | | Result: | Reduced the severity of the keratitis and hasten the onset of resolution.
Had little mild inflammation and very few PMNs infiltration in the corneal stroma.
|
| | References | [1] Paloschi MV, et, al. Cytosolic phospholipase A2-α participates in lipid body formation and PGE2 release in human neutrophils stimulated with an L-amino acid oxidase from Calloselasma rhodostoma venom. Sci Rep. 2020 Jul 3;10(1):10976. DOI:10.1038/s41598-020-67345-3
[2] Tripathi T, et, al. Role of phospholipase A (PLA) inhibitors in attenuating apoptosis of the corneal epithelial cells and mitigation of Acanthamoeba keratitis. Exp Eye Res. 2013 Aug;113:182-91. DOI:10.1016/j.exer.2013.05.021 |
| | CAY10650 Preparation Products And Raw materials |
|